Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

63.02
BATS BZX Real-Time Price
As of 1:52pm ET
 -1.20 / -1.87%
Today’s Change
45.45
Today|||52-Week Range
68.12
+6.38%
Year-to-Date
Share Buyback Party Comes to an End
11:53am / GuruFocus News - Paid Partner Content
Wall Street Sells Off on Worries Over Clinton-Trump Showdown
Sep 26 / TheStreet.com - Paid Partner Content
Share Repurchase Party Comes to an End
11:29am / GuruFocus News - Paid Partner Content
As Humira Alternative Gets FDA Approval, Is Abbvie in Trouble?
Sep 26 / Zacks.com - Paid Partner Content
How Oncology Could Move the Needle for Johnson & Johnson's Stock
9:15am / MotleyFool.com - Paid Partner Content
Stocks Fall Ahead of Clinton-Trump Debate, Crude Rallies
Sep 26 / TheStreet.com - Paid Partner Content
Bristol-Myers, Nektar Tie-Up for Opdivo/NKTR-214 Combo
Sep 28 / Zacks.com - Paid Partner Content
Stock Market News for September 26, 2016
Sep 26 / Zacks.com - Paid Partner Content
Better Buy: Johnson & Johnson vs. AbbVie
Sep 28 / MotleyFool.com - Paid Partner Content
AbbVie (ABBV) HCV Combination Drug Positive in Phase IIIb
Sep 26 / Zacks.com - Paid Partner Content
Gilead Sciences Stock Downgraded: 3 Things You Need to Know
Sep 28 / MotleyFool.com - Paid Partner Content
Amgen's Biosimilar of Abbvie's Humira Gets FDA Approval
Sep 26 / Zacks.com - Paid Partner Content
Stock Research Reports for Amazon, Boeing & MasterCard
Sep 28 / Zacks.com - Paid Partner Content
3 Dirt-Cheap Dividend Stocks You Can Buy Right Now
Sep 24 / MotleyFool.com - Paid Partner Content
FDA Approval of Amjevita Need Not Worry AbbVie Shareholders
Sep 28 / GuruFocus News - Paid Partner Content
3 Dividend Investing Tips That Could Earn You Thousands
Sep 23 / MotleyFool.com - Paid Partner Content
Momenta to Regain Rights to Humira Biosimilar from Shire
Sep 28 / Zacks.com - Paid Partner Content
3 Top Dividend Stocks for Your Roth IRA
Sep 22 / MotleyFool.com - Paid Partner Content
3 Critical FDA Decisions You Can't Afford to Miss
Sep 27 / MotleyFool.com - Paid Partner Content
The Pros and Cons of Buying Gilead Sciences Stock
Sep 22 / MotleyFool.com - Paid Partner Content
AbbVie (ABBV) Files sNDA for Blood Cancer Drug Imbruvica
Sep 27 / Zacks.com - Paid Partner Content
Here's Why Sarepta Therapeutics, Inc's Stock is Jumping Again
Sep 20 / MotleyFool.com - Paid Partner Content
Biosimilars in Limelight on FDA Approval of Amgen Drug
Sep 27 / Zacks.com - Paid Partner Content
Better Buy: Pfizer Inc. vs. AbbVie Inc.
Sep 15 / MotleyFool.com - Paid Partner Content